Alex is Chief Strategy and Operating Officer of enGene. Prior to enGene, he was the President, Chief Executive Officer, and co-founder of Mythic Therapeutics, Inc., a clinical-stage product-platform company developing a pipeline of antibody-drug conjugates (“ADCs”). In this role, Alex co-invented the company’s technology platform and lead program, raised more than $130 million across several financing rounds and helped grow the company into an emerging ADC innovator. Prior to Mythic, Alex worked as an associate at Flagship Pioneering Inc., where he was part of the co-founding team of Cogen Therapeutics (now Repertoire Immune Medicines). Alex holds a B.A. in Biochemistry from Oberlin College and Ph.D. in Biophysics from Harvard University.

• 

  Chief Strategy Officer (CSO) in enGene

  Mainstreaming Gene Therapy

• 

  Chief Operating Officer (COO) in enGene

  Mainstreaming Gene Therapy